- Home
- OPT vs PENG Comparison
OPT vs PENG Comparison
Compare OPT & PENG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPT
- PENG
- Stock Information
- Founded
- OPT 1984
- PENG 1988
- Country
- OPT Australia
- PENG Cayman Islands
- Employees
- OPT N/A
- PENG N/A
- Industry
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- PENG Semiconductors
- Sector
- OPT Health Care
- PENG Technology
- Exchange
- OPT Nasdaq
- PENG Nasdaq
- Market Cap
- OPT 767.9M
- PENG 830.2M
- IPO Year
- OPT 2020
- PENG 2017
- Fundamental
- Price
- OPT $3.60
- PENG $19.98
- Analyst Decision
- OPT Strong Buy
- PENG Strong Buy
- Analyst Count
- OPT 1
- PENG 6
- Target Price
- OPT $12.00
- PENG $24.17
- AVG Volume (30 Days)
- OPT 9.2K
- PENG 982.9K
- Earning Date
- OPT 08-30-2024
- PENG 01-08-2025
- Dividend Yield
- OPT N/A
- PENG N/A
- EPS Growth
- OPT N/A
- PENG N/A
- EPS
- OPT N/A
- PENG N/A
- Revenue
- OPT $261,859.00
- PENG $1,170,796,000.00
- Revenue This Year
- OPT N/A
- PENG N/A
- Revenue Next Year
- OPT $46,864.64
- PENG N/A
- P/E Ratio
- OPT N/A
- PENG N/A
- Revenue Growth
- OPT N/A
- PENG N/A
- 52 Week Low
- OPT $1.79
- PENG $14.87
- 52 Week High
- OPT $5.45
- PENG $29.81
- Technical
- Relative Strength Index (RSI)
- OPT 52.65
- PENG N/A
- Support Level
- OPT $3.15
- PENG N/A
- Resistance Level
- OPT $3.39
- PENG N/A
- Average True Range (ATR)
- OPT 0.17
- PENG 0.00
- MACD
- OPT 0.05
- PENG 0.00
- Stochastic Oscillator
- OPT 72.31
- PENG 0.00
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.